ICMR moves for developing Indigenous COVID-19 Vaccine

New Delhi: India might have its own vaccine for COVID 19. Indian Council of Medical Research (ICMR), country’s apex research institute, is in earnest and has moved forward in its quest.

Indian Council of Medical Research (ICMR) and Bharat Biotech International Limited (BBIL) have partnered to develop a fully indigenous vaccine for COVID-19 using the virus strain isolated at ICMR’s National Institute of Virology (NIV), Pune.

The strain has been successfully transferred from NIV to Bharat Biotech International Ltd. (BBIL). Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approvals to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine.

Related Posts

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

Patients for Patient Safety Foundation (PFPSF) Partners with CAHO to RollOut an Excellence Program New Delhi: Thanks to some well-meaning organizations, patients are going to be lord of all they…

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore